1. Home
  2. DLNG vs BMEA Comparison

DLNG vs BMEA Comparison

Compare DLNG & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dynagas LNG Partners LP

DLNG

Dynagas LNG Partners LP

HOLD

Current Price

$3.85

Market Cap

142.3M

ML Signal

HOLD

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$1.55

Market Cap

138.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DLNG
BMEA
Founded
2013
2017
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
142.3M
138.1M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
DLNG
BMEA
Price
$3.85
$1.55
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$9.83
AVG Volume (30 Days)
63.9K
1.6M
Earning Date
05-26-2026
05-12-2026
Dividend Yield
5.18%
N/A
EPS Growth
N/A
69.19
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.10
N/A
P/E Ratio
$3.04
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.40
$0.87
52 Week High
$4.45
$3.07

Technical Indicators

Market Signals
Indicator
DLNG
BMEA
Relative Strength Index (RSI) 41.25 46.40
Support Level $3.73 $1.50
Resistance Level $4.25 $1.66
Average True Range (ATR) 0.11 0.15
MACD -0.01 -0.03
Stochastic Oscillator 15.15 33.33

Price Performance

Historical Comparison
DLNG
BMEA

About DLNG Dynagas LNG Partners LP

Dynagas LNG Partners LP is a limited partnership company focused on owning and operating high specification and versatile LNG carriers that are employed on multi-year contracts with international energy companies, providing the benefits of stable cash flows and high utilization rates. The company defines charters of two years or more as multi-year charters. Its current LNG Carrier fleet is optimized for trading flexibility. In addition to conventional trade, part of LNG Carrier fleet is assigned with Ice Class 1A FS notation and is winterized, which enables trade in subzero and ice bound conditions.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

Share on Social Networks: